Hanusch Krankenhaus Der Wiener Gebietskrankenkasse — Clinical Trial Site

53 Registered trials

24 Currently recruiting

Organisation

Hanusch Krankenhaus Der Wiener Gebietskrankenkasse

Location

Vienna, Austria

Identifier

ORG-100023126

Address

Heinrich-Collin-Strasse 30/1100, Penzing, 1140, Austria

Departments

#3602: Haematology and Oncology
040001: 1. Medizinische Abteilung
1. Medical Department
1. Medizinische Abteilung, Nephrologie
2. Medizinische Abteilung
2000: 3.Med.Abteilung, Hämatologie u. Onkologie
2103: Medizinische Abteilung für Hämatologie und Onkologie
2161_Med. Dep, Hematolgy and Oncology
3. Med. Abteilung für Hämatologie und Onkologie
3. Medical Department
3. Medical Department - Hematology and Oncoloy
3. Medical department – Department of hematology & Oncology
3. Medical Department for Hematology and Oncology
3. Medizinische Abteilung
3. Medizinischen Abteilung Hämatologie & Onkologie
3. Medizinsiche Abteilung
3.Medizinische Abteilung
3.Medizinische Abteilung – Abteilung für Hämatologie & Onkologie
3.Medizinische Abteilung für Hämatologie und Onkologie
3rd Medical Department
3rd Medical Department Division of Hematology and Oncology
3rd Medical Department - Hematology and oncology
3rd Medical Department for Hematology and Oncology
3rd Medical Department of Hematology and Oncology
3rd Medical Department, Division of Hematology and Oncology
3rd Medical Division
Department for Eye Diseases
Department of Hematology and Oncology
Department of Internal Medicine
Department of Internal Medicine III, Hematology and Oncology
Haematology & Oncology
Hanusch Hospital, 3rd Medical Department
Hematology
III. Medizinische Abteilung
Med.Dept. III, Pavilion 6
Medical department
Urologische Abteilung
Zentrum f. Med. Genetik

Clinical trials at this site (53)

Search interface

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi… Recruiting

2023-504599-10-00 Chronic lymphocytic leukemia recurrent 4 2022-03-29
BRCA-P: A Cancer Prevention study to determine if Denosumab can prevent Breast Cancer Development in Women carrying a BRCA1 Germline Mutatio… Recruiting

2024-513734-38-00 Prevention of breast cancer in women with a BRCA1 germl 5 2019-07-03
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Defined by parent protocol. The study will enroll all a 10 2018-12-21
Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al… Ended

2023-505673-32-00 Hypophosphatasia 5 2024-08-05
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended

2023-506948-17-00 Previously Untreated Chronic Lymphocytic Leukemia 5 2024-04-05
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 previously untreated aggressive B-cell lymphoma 4 2023-03-16
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-11-09
A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended

2023-508897-27-00 Multiple Myeloma 5 2022-04-28
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Newly diagnosed Philadelphia-negative B-cell precursor 5 2022-02-17
Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with n… Ended

2024-515581-13-00 Isatuximab in combination with Lenalidomide-Dexamethaso 4 2021-10-20
Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended

2024-514473-21-00 Primary diffuse large B-cell lymphoma (DLBCL) of the ce 5 2021-06-21
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended

2023-507153-16-00 Higher-Risk Myelodysplastic Syndrome 5 2020-11-18
Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence Ended

2024-511832-29-00 High risk adenocarcinoma of the prostate after radical 4 2020-08-05
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre… Ended

2023-509349-11-00 Previously untreated Chronic Lymphocytic Leukemia Witho 5 2019-03-22
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with… Ended

2023-508463-71-00 Newly Diagnosed Philadelphia Chromosome-Positive Acute 5 2018-11-30
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Asciminib treatment optimization in ≥ 3rd line CML-CP Ended

2024-511381-36-00 Chronic Myelogenous Leukemia in chronic phase (CML-CP) 5 2021-10-13
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended

2023-507002-14-00 treatment-naïve or relapsed/refractory chronic lymphocy 4 2021-05-20